Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119530 | 0.88 | TSHR (0.60) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL3292782 | 0.86 | TSHR (0.75) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL1119477 | 0.86 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL8995565 | 0.84 | TSHR (0.56) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL3028162 | 0.84 | TSHR (0.56) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL18913824 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL30758863 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL22464 | 0.82 | LOXL2 (0.61) | TSHRLOXL2KCNJ1KCNH2IDO1 | |
| SCHEMBL2588477 | 0.80 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL250472 | 0.80 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104202999-B | Nitro amino derivant is reduced in feedstuff the purposes of methane discharge of ruminant | 帝斯曼知识产权资产管理有限公司 | 2016-11-16 | — | — | CN | claimed |
| CN-105472995-A | Use of feed composition for reducing methane emission in ru-minants, and/or to improve ruminant performance | DSM IP ASSETS BV | 2016-04-06 | — | — | CN | claimed |
| CN-104202999-A | Use of para nitro amino derivatives in feed for reducing me-thane emission in ruminants | DSM IP ASSETS BV | 2014-12-10 | — | — | CN | claimed |
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| CN-1224426-A | 3-descladinose-2, 3-anhydroerythromycin derivatives | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | claimed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| EP-0413020-A1 | PYRAZOLOTRIAZOLES AND PROCESSES FOR THEIR FORMATION | EASTMAN KODAK COMPANY (US) | 1991-02-20 | — | — | EP | claimed |
| WO-1990010004-A1 | PYRAZOLOTRIAZOLES AND PROCESSES FOR THEIR FORMATION | EASTMAN KODAK COMPANY (US) | 1990-09-07 | — | — | WO | claimed |
| US-4914209-A | PHOTOGRAPHIC COUPLERS | EASTMAN KODAK COMPANY (US) | 1990-04-03 | — | — | US | claimed |
| US-4689411-A | ANTIBIOTICS | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1987-08-25 | — | — | US | claimed |
| US-4603014-A | Thiazolinoazetidinone derivatives and process for the preparation of the same | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1986-07-29 | — | — | US | claimed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-4175197-A | 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4115400-A | 1-Azoniabicyclo[3.1.0]hexanes | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081450-A | 1,3,4-Trisubstituted-4-arylpiperidines and their preparation | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | TSHR 1486/4885LOXL2 523/4885KCNJ1 1673/4885 |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | KCNH1, KCNJ2, KCNH2 | TSHR 1694/4885LOXL2 3529/4885KCNJ1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.